Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Septerna, Inc. (SEPN)
NASDAQ:SEPN
Holding SEPN?
Track your performance easily
SEPN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$18.62 - $26.34
Previous Close$22
Volume152.47K
Average Volume (3M)342.36K
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)$148.84M
Total Debt (Recent Filing)$12.27M
Price to Earnings (P/E)―
Beta3.67
Next Earnings
Nov 20, 2024EPS Estimate
-$5.88Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,940,294
10 Day Avg. Volume142,522
30 Day Avg. Volume342,362
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-12.29
Price to Sales (P/S)5920.23
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.00
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$40.50Price Target Upside84.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Septerna, Inc. News
PremiumCompany Announcements
Septerna, Inc. Reports Q3 2024 Financials and ProgressBulls Say, Bears Say
Bulls Say
Clinical Progress And ValidationSEP-786's preclinical data should translate well to the clinic, with good PK/PD properties in preclinical models being highly predictive of future clinical activity in humans.
Drug Development And InnovationSepterna's Native Complex Platform uses advanced structural biochemistry techniques to model GPCR actions, leading to more precise drug design.
Market Potential And DifferentiationLead asset SEP-786 seeks to differentiate from daily injectable PTH drugs with its convenient, oral formulation.
Bears Say
Corporate GovernanceInvestors should be aware that the firm may have a conflict of interest that could affect the objectivity of the report.
Financial PerformanceROIC - Current year estimate is 0%.
Product DevelopmentThe potential toxicity issue for INCY's EP262 creates an overhang on MRGPRX2 as a target, but leaves SEP-631 as a non-differentiated option until more data is available.
---
Options Prices
Currently, No data available
---
Ownership Overview
SEPN FAQ
What was Septerna, Inc.’s price range in the past 12 months?
Septerna, Inc. lowest stock price was $18.62 and its highest was $26.34 in the past 12 months.
What is Septerna, Inc.’s market cap?
Currently, no data Available
When is Septerna, Inc.’s upcoming earnings report date?
Septerna, Inc.’s upcoming earnings report date is Nov 20, 2024 which is 6 days ago.
How were Septerna, Inc.’s earnings last quarter?
Currently, no data Available
Is Septerna, Inc. overvalued?
According to Wall Street analysts Septerna, Inc.’s price is currently Undervalued.
Does Septerna, Inc. pay dividends?
Septerna, Inc. does not currently pay dividends.
What is Septerna, Inc.’s EPS estimate?
Septerna, Inc.’s EPS estimate is -$5.88.
How many shares outstanding does Septerna, Inc. have?
Septerna, Inc. has 44,402,740 shares outstanding.
What happened to Septerna, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Septerna, Inc.?
Currently, no hedge funds are holding shares in SEPN
---
Septerna, Inc. Stock Smart Score
Company Description
Septerna, Inc.
Septerna is a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by its proprietary Native Complex Platform. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Our lead product candidate, SEP-786, is a clinical-stage, oral small molecule agonist targeting PTH1R for the treatment of hypoparathyroidism. We have successfully completed Investigational New Drug (IND)-enabling studies and have initiated a Phase 1 clinical trial to assess preliminary safety, tolerability, PK, and PD of SEP-786.
---
SEPN Stock 12 Month Forecast
Average Price Target
$40.50
▲(84.09% Upside)
Technical Analysis
Best Analysts Covering SEPN
1 Year
1 Year Success Rate
0/1 ratings generated profit
1 Year Average Return
-2.20%
initiated a buy rating 6 days ago
Copying Yaron Werber's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -2.20% per trade.
---